PRECISELY ENGINEERING THE FUTURE OF OPHTHALMOLOGYTM

ABOUT ENVISIA THERAPEUTICS™

envisia1In 2013, Liquidia Technologies formed a new company, Envisia Therapeutics,™ to develop novel therapeutics that can address critical unmet needs in ophthalmology.

OPHTHALMOLOGY PROGRAMS

opthalmology2As many as 285 million people suffer from disease-related visual impairments and blindness, but an estimated 80 percent of these visual impairments are actually preventable.

THE PRINT® TECHNOLOGY

technology2The PRINT® technology is a proprietary system capable of engineering highly precise microparticle and nanoparticle systems.

Copyright 2013 Envisia Therapeutics